Category: Data


Impella Support Pre-PCI for AMICS is Associated with Higher Survival in Women

Reference: J Interven Cardiol 2016; 29:248–256. Cardiogenic shock (CS) is the leading cause of death after acute myocardial infarction (AMI) and occurs in up to 10% of cases.1 Notably, the incidence of CS is higher in women presenting with STEMI than men (11.6% vs. 8.3%, p < 0.01).2   Previous studies evaluating the impact of CS … Continue reading “Impella Support Pre-PCI for AMICS is Associated with Higher Survival in Women”

INOVA Heart and Vascular Heart Recovery Initiative

Instituting a Cardiogenic Shock Protocol to Improve Outcomes Alexander Truesdell, MD and Behnam Tehrani, MD, interventional cardiologists at INOVA Heart and Vascular Institute discuss their experience implementing a cardiogenic shock protocol at INOVA. Data from their experience was recently published in the Journal of the American College of Cardiology. After Inova instituted a best practice … Continue reading “INOVA Heart and Vascular Heart Recovery Initiative”

Improving Survival in Cardiogenic Shock by Adopting a Uniform Approach to Systems of Care

Reference: J Am Coll Cardiol 2018; 72:1972-80 Cardiogenic shock continues to be the leading cause of death in patients with acute myocardial infarction (AMI).1 Despite implementation of guideline-recommended early revascularization, mortality rates in AMI complicated by cardiogenic shock (AMICS) remains constant at about 50%. Given that about 60,000 patients with AMI develop CS every year,2 … Continue reading “Improving Survival in Cardiogenic Shock by Adopting a Uniform Approach to Systems of Care”

The Door-to-Unloading (DTU) STEMI Safety & Feasibility Trial

Navin Kapur, MD, executive director of the CardioVascular Center for Research and Innovation at Tufts Medical Center, discusses the results of the FDA STEMI Door-to-Unloading safety and feasibility randomized controlled trial. These results were presented at the American Heart Association Scientific Sessions 2018 in Chicago on Sunday, November 11. What did we learn from this pilot … Continue reading “The Door-to-Unloading (DTU) STEMI Safety & Feasibility Trial”

National Cardiogenic Shock Initiative: 1 Year Later

Video Chapters: The Impact of The Cardiogenic Shock Initiative (NCSI): One Year Later William O’Neill, MD Advances in the Treatment of Cardiovascular Disease in Women: PCI, MI, Shock, Myocarditis, SCAD, and Post-partum Cardiomyopathy Cindy Grines, MD Understanding the Importance of Ventricular Unloading in Management of AMI and Cardiogenic Shock Navin Kapur, MD Subscribe, or join the … Continue reading “National Cardiogenic Shock Initiative: 1 Year Later”

Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device

Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) database. The clinical publication highlights best practice protocols based on real-world evidence that is showing improved outcomes in cardiogenic shock. This clinical evidence is derived from Abiomed’s observational , commercial IQ database. In patients with AMICS receiving … Continue reading “Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device”

Updates on the Detroit Cardiogenic Shock Initiative: It’s Gone National

Dr. Bill O’Neill of Henry Ford Hospital and Dr. Ted Schreiber of Detroit Medical Center discuss updates on the Detroit Cardiogenic Shock Initiative (CSI). Partnering hospital systems participating in DCSI use a defined protocol for early placement of Impella in patients in cardiogenic shock. Since July, initial results from a small sampling of patients show … Continue reading “Updates on the Detroit Cardiogenic Shock Initiative: It’s Gone National”

IMPRESS in Severe Shock Trial: Looking Closer at the Data

For patients with cardiogenic shock (CS), intra-aortic balloon pump (IABP) had been an important tool for maintaining patients and improving survival after percutaneous coronary intervention (PCI). Randomized controlled trials, however, have found very little evidence to support the notion that IABP is helpful for reducing mortality or improving hemodynamics for patients with CS.1,2 The Impella® … Continue reading “IMPRESS in Severe Shock Trial: Looking Closer at the Data”